Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Nadecnemab, an antibody targeting GFRA3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Licaminlimab, an antibody targeting TNF.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Daxdilimab, an antibody targeting LILRA4.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Atibuclimab, an antibody targeting CD14.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Enibarcimab, an antibody targeting ADM.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ulenistamab, an antibody targeting PAUF.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Zinlirvimab, an antibody targeting HIV-1 gp120 V3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Visugromab, an antibody targeting GDF15.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ubamatamab, an antibody targeting MUC16 × CD3E.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Trontinemab, an antibody targeting APP Abeta 1-40 × TFRC.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Teropavimab, an antibody targeting HIV-1 gp120 CD4bs.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Simridarlimab, an antibody targeting IAP × PD-L1.